# US 2025/0375389 A1 · Lipid nanoparticle compositions comprising phospholipid derivatives and related uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375389 A1
- Document ID: US20250375389A1
- Status: Published application
- Kind: A1
- Application number: 19/099,092
- Filed: 2023-07-28
- Published: 2025-12-11
- Earliest claimed: 2022-07-29
- Assignees: ModernaTX, Inc.
- Applicants: ModernaTX, Inc.
- Inventors: Jaclyn MILTON; Mohindra SEEPERSAUD; Karthik RAMACHANDRAN; Russell B. UMSTEAD; Calvin Loishiye MARAMBO; Mark CORNEBISE
- Web page: https://patentgrep.com/patent/US20250375389A1

## CPC

- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5192: {Processes}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides lipid assemblies suitable for delivery of therapeutic agents to hematopoietic stem and progenitor cells (HSPCs), wherein the lipid assemblies comprise a phosphatidylserine phospholipid. The present disclosure also provides therapeutic and diagnostic uses related to the lipid assemblies.

## Claims

### Claim 1

A lipid assembly comprising a phosphatidylserine phospholipid, an ionizable lipid, and a structural lipid, wherein the phosphatidylserine phospholipid is of Formula (PL-I):
or a salt thereof, wherein:
n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
A is of the formula:
each instance of L2 is independently a bond or an optionally substituted C1-6 alkylene, wherein one methylene unit of the optionally substituted C1-6 alkylene is optionally replaced with —O—, —N(RN)—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, or —NRNC(O)N(RN)—;
each instance of R2 is independently cholesterol, optionally substituted cycloalkyl, optionally substituted C1-30 alkyl, optionally substituted C1-30 alkenyl, or optionally substituted C1-30 alkynyl; optionally wherein one or more methylene units of the optionally substituted C1-30 alkyl, optionally substituted C1-30 alkenyl, or optionally substituted C1-30 alkynyl are independently replaced with optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, —N(RN)—, —O—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —NRNC(O)N(RN)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, —C(O)S—, —SC(O)—, —C(═NRN)—, —C(═NRN)N(RN)—, —NRNC(═NRN)—, —NRNC(═NRN)N(RN)—, —C(S)—, —C(S)N(RN)—, —NRNC(S)—, —NRNC(S)N(RN)—, —S(O)—, —OS(O)—, —S(O)O—, —OS(O)O—, —OS(O)2—, —S(O)2O—, —OS(O)2O—, —N(RN)S(O)—, —S(O)N(RN)—, —N(RN)S(O)N(RN)—, —OS(O)N(RN)—, —N(RN)S(O)O—, —S(O)2—, —N(RN)S(O)2—, —S(O)2N(RN)—, —N(RN)S(O)2N(RN)—, —OS(O)2N(RN)—, or —N(RN)S(O)2O—;
each instance of RN is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group;
Ring B is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
p is 1 or 2.

### Claim 2

A population of lipid assemblies comprising a phosphatidylserine phospholipid, an ionizable lipid, and a structural lipid, wherein the phosphatidylserine phospholipid is of Formula (PL-I):
or a salt thereof, wherein:
n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
A is of the formula:
each instance of L2 is independently a bond or an optionally substituted C1-6 alkylene, wherein one methylene unit of the optionally substituted C1-6 alkylene is optionally replaced with —O—, —N(RN)—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, or —NRNC(O)N(RN)—;
each instance of R2 is independently cholesterol, optionally substituted cycloalkyl, optionally substituted C1-30 alkyl, optionally substituted C1-30 alkenyl, or optionally substituted C1-30 alkynyl; optionally wherein one or more methylene units of the optionally substituted C1-30 alkyl, optionally substituted C1-30 alkenyl, or optionally substituted C1-30 alkynyl are independently replaced with optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, —N(RN)—, —O—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —NRNC(O)N(RN)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, —C(O)S—, —SC(O)—, —C(═NRN)—, —C(═NRN)N(RN)—, —NRNC(═NRN)—, —NRNC(═NRN)N(RN)—, —C(S)—, —C(S)N(RN)—, —NRNC(S)—, —NRNC(S)N(RN)—, —S(O)—, —OS(O)—, —S(O)O—, —OS(O)O—, —OS(O)2—, —S(O)2O—, —OS(O)2O—, —N(RN)S(O)—, —S(O)N(RN)—, —N(RN)S(O)N(RN)—, —OS(O)N(RN)—, —N(RN)S(O)O—, —S(O)2—, —N(RN)S(O)2—, —S(O)2N(RN)—, —N(RN)S(O)2N(RN)—, —OS(O)2N(RN)—, or —N(RN)S(O)2O—;
each instance of RN is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group;
Ring B is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
p is 1 or 2.

### Claim 3 (depends on 1, 2)

The lipid assembly or the population of lipid assemblies of claim 1 or 2, wherein the phosphatidylserine phospholipid is of Formula (PL-Ia):
or a salt thereof.

### Claim 4 (depends on 1, 2, 3)

The lipid assembly or the population of lipid assemblies of any one of claims 1 to 3, wherein n is 0 and m is 1.

### Claim 5

The lipid assembly or the population of lipid assemblies of any one of the preceding claims, wherein the phosphatidylserine phospholipid is of Formula (PL-Ib):
or a salt thereof.

### Claim 6

The lipid assembly or the population of lipid assemblies of any one of the preceding claims, wherein each instance of R2 is independently C1-30, C9-21, C11-19, or C13-17 alkyl or C1-30, C9-21, C11-19, or C13-17 alkenyl.

### Claim 7

The lipid assembly or the population of lipid assemblies of any one of the preceding claims, wherein the phosphatidylserine phospholipid is
or a salt thereof.

### Claim 8

The lipid assembly or the population of lipid assemblies of any one of the preceding claims, comprising between about 1 mol % to about 10 mol %, about 1 mol % to about 8 mol %, about 1 mol % to about 5 mol %, or about 2 mol % to about 5 mol % of the phosphatidylserine phospholipid; and/or
comprising about 1 mol %, about 2 mol %, about 3 mol %, about 4 mol %, or about 5 mol % of the phosphatidylserine phospholipid.

### Claim 9

The lipid assembly or the population of lipid assemblies of any one of the preceding claims, comprising about 30 mol % to about 50 mol %, about 30 mol % to about 45 mol %, about 30 mol % to about 40 mol %, about 35 mol % to about 45 mol %, or about 35 mol % to about 40 mol % of the ionizable lipid; and/or
comprising about 30 mol %, about 35 mol %, about 40 mol %, about 45 mol %, or about 50 mol % of the ionizable lipid; and/or
wherein the ionizable lipid is compound 301 or compound 22.

### Claim 10

The lipid assembly or the population of lipid assemblies of any one of the preceding claims, comprising about 15 mol % to about 45 mol %, about 20 mol % to about 45 mol %, about 25 mol % to about 45 mol %, about 30 mol % to about 45 mol %, about 35 mol % to about 45 mol %, or about 40 mol % to about 45 mol % of the structural lipid; and/or
comprising about 15 mol %, about 20 mol %, about 25 mol %, about 30 mol %, about 35 mol %, about 40 mol %, or about 45 mol % of the structural lipid; and/or
wherein the structural lipid is cholesterol.

### Claim 11

The lipid assembly or the population of lipid assemblies of any one of the preceding claims, further comprising a second phospholipid; optionally:
comprising about 10 mol % to about 30 mol %, 10 mol % to about 25 mol %, 10 mol % to about 20 mol %, about 15 mol % to about 25 mol %, or about 15 mol % to about 20 mol % of the second phospholipid; and/or:
comprising about 10 mol %, about 15 mol %, about 18 mol %, about 20 mol %, about 22 mol %, about 25 mol %, or about 30 mol % of the second phospholipid; and/or
wherein the second phospholipid is DSPC, DOPE, DOPC, POPE, or POPC.

### Claim 12

The lipid assembly or the population of lipid assemblies of any one of the preceding claims, being free of PEG lipid.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The lipid assembly or the population of lipid assemblies of any one of claims 1 to 11, further comprising a PEG lipid; optionally:
comprising about 0.5 mol % to about 10 mol %, about 0.5 mol % to about 5 mol %, about 1 mol % to about 5 mol %, or about 1 mol % to about 3 mol % of the PEG lipid; and/or
comprising about 0.5 mol %, about 1 mol %, about 2 mol %, about 3 mol %, about 4 mol %, or about 5 mol % of the PEG lipid; and/or
wherein the PEG lipid is PL-02.

### Claim 14

The lipid assembly or the population of lipid assemblies of any one of the preceding claims, having a pH value lower than the pKa value of the ionizable lipid; and/or
having a pH value of about 4.0±2.0, about 4.0±1.5, about 4.0±1.4, about 4.0±1.3, about 4.0±1.2, about 4.0±1.1, about 4.0±1.0, about 4.0±0.9, about 4.0±0.8, about 4.0±0.7, about 4.0±0.6, about 4.0±0.5, about 4.0±0.4, about 4.0±0.3, about 4.0±0.2, or about 4.0±0.1; or
having a pH value of about 5.0±2.0, about 5.0±1.5, about 5.0±1.4, about 5.0±1.3, about 5.0±1.2, about 5.0±1.1, about 5.0±1.0, about 5.0±0.9, about 5.0±0.8, about 5.0±0.7, about 5.0±0.6, about 5.0±0.5, about 5.0±0.4, about 5.0±0.3, about 5.0±0.2, or about 5.0±0.1.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The lipid assembly or the population of lipid assemblies of any one of claims 1 to 13, having a pH value higher than the pKa value of the ionizable lipid; and/or
having a pH value of about 8.0±2.0, about 8.0±1.5, about 8.0±1.4, about 8.0±1.3, about 8.0±1.2, about 8.0±1.1, about 8.0±1.0, about 8.0±0.9, about 8.0±0.8, about 8.0±0.7, about 8.0±0.6, about 8.0±0.5, about 8.0±0.4, about 8.0±0.3, about 8.0±0.2, or about 8.0±0.1; or
having a pH value of about 9.0±3.0, about 9.0±2.0, about 9.0±1.5, about 9.0±1.4, about 9.0±1.3, about 9.0±1.2, about 9.0±1.1, about 9.0±1.0, about 9.0±0.9, about 9.0±0.8, about 9.0±0.7, about 9.0±0.6, about 9.0±0.5, about 9.0±0.4, about 9.0±0.3, about 9.0±0.2, or about 9.0±0.1; or
having a pH value of about 12.0±2.0, about 12.0±1.5, about 12.0±1.4, about 12.0±1.3, about 12.0±1.2, about 12.0±1.1, about 12.0±1.0, about 12.0±0.9, about 12.0±0.8, about 12.0±0.7, about 12.0±0.6, about 12.0±0.5, about 12.0±0.4, about 12.0±0.3, about 12.0±0.2, or about 12.0±0.1.

### Claim 16

The lipid assembly or the population of lipid assemblies of any preceding claim, having a zeta potential between about −40 mV to about −5 mV, about −30 mV to about −5 mV, about −20 mV to about −5 mV, about −40 mV to about −10 mV, about −30 mV to about −10 mv, or about −20 mV to about −10 mV when measured in 0.1N PBS at pH 7.5.

### Claim 17

The lipid assembly or the population of lipid assemblies of any one of the preceding claims, being free of therapeutic agent.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The lipid assembly or the population of lipid assemblies of any one of claims 1 to 16, further comprising a therapeutic agent; optionally wherein the therapeutic agent is an RNA.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A pharmaceutical composition comprising the lipid assembly or the population of lipid assemblies of any one of claims 1 to 18 and one or more pharmaceutically acceptable carriers or excipients.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method of preparing the lipid assembly or the population population of lipid assemblies of any one of claims 1 to 18.

### Claim 21 (depends on 19)

A method of preparing the pharmaceutical composition of claim 19.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method of delivering a therapeutic agent to a hematopoietic stem and progenitor cell (HSPC) in a subject, comprising administering to the subject the lipid assembly, the population of lipid assemblies, or the pharmaceutical composition of any one of claims 1 to 19.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The lipid assembly, the population of lipid assemblies, or the pharmaceutical composition of any one of claims 1 to 19 for use in delivering a therapeutic agent to a hematopoietic stem and progenitor cell (HSPC) in a subject.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

Use of lipid assembly, the population of lipid assemblies, or the pharmaceutical composition of any one of claims 1 to 19 in the manufacture of a medicament for delivering a therapeutic agent to a hematopoietic stem and progenitor cell (HSPC) in a subject.

### Claim 25 (depends on 22, 23, 24)

The method, lipid assembly, population, pharmaceutical composition, or use of any one of claims 22 to 24, wherein:
the HSPC is in the spleen of the subject; or
the HSPC is in the bone marrow of the subject.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method of treating or preventing a disease or disorder, the method comprising administering to a subject in need thereof the lipid assembly, the population of lipid assemblies, or the pharmaceutical composition of any one of claims 1 to 19.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The lipid assembly, the population of lipid assemblies, or the pharmaceutical composition of any one of claims 1 to 19 for use in treating or preventing a disease or disorder in a subject.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

Use of the lipid assembly, the population of lipid assemblies, or the pharmaceutical composition of any one of claims 1 to 19 in the manufacture of a medicament for treating or preventing a disease or disorder in a subject.

### Claim 29 (depends on 26, 27, 28)

The method, lipid assembly, population, pharmaceutical composition, or use of any one of claims 26 to 28, wherein:
the subject is human; and/or
the disease or disorder is a spleen disease or a spleen disorder; or
the disease or disorder is a bone marrow disease or a bone marrow disorder.

### Claim 30

A process of preparing a nanoparticle, the process comprising contacting an aqueous stream comprising a phosphatidylserine lipid with an organic stream comprising an ionizable lipid and a structural lipid, thereby obtaining a mixed product; optionally:
wherein the organic stream further comprises a PEG lipid; and/or
wherein the pH of the aqueous stream is lower than the pKa of the ionizable lipid.

### Claim 31 (depends on 30)

The process of claim 30, wherein the process further comprises subjecting the mixed product to an in-line dilution; optionally:
wherein the in-line dilution lowers an organic solvent content of the mixed product; and/or
wherein the in-line dilution raises the pH of the mixed product above the pKa of the ionizable lipid.

### Claim 32 (depends on 30, 31)

The process of claim 30 or 31, wherein the phosphatidylserine phospholipid is DMPS; and/or
wherein the ionizable lipid is Compound 22 or Compound 301.

### Claim 33 (depends on 30, 31, 32)

A nanoparticle prepared by the process of any one of claims 30 to 32.
